TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03121456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET SCAN
Description: REALIZATION OF INITIAL 18F-FDG PET SCAN (PRE THERAPEUTIC), THEN BETWEEN CYCLE 2 DAY 10 AND CYCLE 3 DAY 1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI DIFFUSION
Description: REALIZATION OF INITIAL MRI DIFFUSION WITHIN 7 DAYS AFTER INITIAL 18F-FDG PET SCAN, THEN WITHIN 7 DAYS AFTER 18F-FDG PET SCAN 1.
Study: NCT00928512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinmab
Description: Secukinumab was supplied as a 150mg lyophiized cake in individual glass vials each. The study drug dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinmab
Description: Secukinumab was supplied as a 150mg lyophiized cake in individual glass vials each. The study drug dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinmab
Description: Secukinumab was supplied as a 150mg lyophiized cake in individual glass vials each. The study drug dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinmab
Description: Secukinumab was supplied as a 150mg lyophiized cake in individual glass vials each. The study drug dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Secukinumab placebo was supplied as a 150mg lyophiized cake in individual glass vials each. The placebo dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.
Study: NCT03816397

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Adalimumab is a fully human monoclonal anti-tumor necrosis factor alpha antibody, a biologic, immunomodulatory drug. Adalimumab 20mg/0.8mL and 40mg/0.8mL is a clear, colorless solution provided in a pre-filled syringe for subcutaneous injection. The formulation is adalimumab, mannitol, polysorbate 80, and water for injection Each pre-filled syringe has a fixed 29-gauge thin wall and ½ inch needle with black protective cover and is intended for a single dose to a single patient.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo solution is a clear, colorless solution provided in a single-use, pre-filled syringe for subcutaneous injection. The placebo is designed to match the characteristics of the citrate-free adalimumab during injection.
Study: NCT02732223

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Functional treatment
Description: Omega 3 fatty acids, plant sterols and polyphenols

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control treatment
Description: placebo supplements
Study: NCT04083794

Intervention type: OTHER
Group type: OTHER
Intervention: Laboratory based assessments
Description: physical maneuvers to assess physiological responses in bone blood flow
Study: NCT02110654

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Study: NCT00827632

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose formulation
Description: Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use.~Dose formula contains 30 ug of ethinyl estradiol (EE) and 150 ug of levonorgestrel (LN) per tablet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose formulation
Description: Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use.~Dose formula contains 30 ug of ethinyl estradiol (EE) and 150 ug of levonorgestrel (LN) per tablet.
Study: NCT04070235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH229 tablets
Description: SH229 400 mg was provided in 4 tablets, 100mg each；SH229 600 mg was provided in 6 tablets , 100mg each；SH229 800 mg in was provided in 8tablets , 100mg each。

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH229 tablets
Description: SH229 400 mg was provided in 4 tablets, 100mg each；SH229 600 mg was provided in 6 tablets , 100mg each；SH229 800 mg in was provided in 8tablets , 100mg each。

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH229 tablets
Description: SH229 400 mg was provided in 4 tablets, 100mg each；SH229 600 mg was provided in 6 tablets , 100mg each；SH229 800 mg in was provided in 8tablets , 100mg each。

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH229 tablets
Description: SH229 400 mg was provided in 4 tablets, 100mg each；SH229 600 mg was provided in 6 tablets , 100mg each；SH229 800 mg in was provided in 8tablets , 100mg each。

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir dihydrochloride
Description: Daclatasvir dihydrochloride was provided in a single tablet of 60 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir dihydrochloride
Description: Daclatasvir dihydrochloride was provided in a single tablet of 60 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir dihydrochloride
Description: Daclatasvir dihydrochloride was provided in a single tablet of 60 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir dihydrochloride
Description: Daclatasvir dihydrochloride was provided in a single tablet of 60 mg.
Study: NCT04137016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application
Study: NCT03579927

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo ASCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study: NCT03503344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO, 240 mg per day (4 x 60mg tablets)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apalutamide
Description: Given PO, 240 mg per day (4 x 60mg tablets)
Study: NCT02110654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate nasal spray
Study: NCT03579927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood-derived Natural Killer Cells
Description: Given CAR.CD19-CD28-zeta-2A-iCasp9-IL15-transduced CB-NK cells IV
Study: NCT04592835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWRX2003
Description: Intramuscularly injection at predefined injection sites~Drug: Placebo Intramuscularly injection at predefined injection sites

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWRX2003
Description: Intramuscularly injection at predefined injection sites~Drug: Placebo Intramuscularly injection at predefined injection sites

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWRX2003
Description: Intramuscularly injection at predefined injection sites~Drug: Placebo Intramuscularly injection at predefined injection sites
Study: NCT03527381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: 40 ppm of exogenous gaseous nitric oxide is supplied directly to the oxygenator in the cardiopulmonary bypass circuit during cardiac surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard CPB
Description: Standard CPB protocol of delivery of air gas mixture to the cardiopulmonary bypass circuit during cardiac surgery.
Study: NCT01120509

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inferior Vena Cava Filter
Description: Inplant of filter in inferior vena cava.
Study: NCT00529282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftobiprole Medocaril
Description: 500 mg every 8 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefepime with or without vancomycin
Description: 120-minute infusion \[250 mL\]
Study: NCT02244307

Intervention type: DRUG
Intervention: alpha-adrenergic blocker
Study: NCT04664712

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Focused shock wave
Description: We delivered 2000 shots per session using a low/medium energy level (range between 0.01 and 0.175 milliJoule/mm2) depending on the patient's tolerance during treatment with a frequency of 4 Hz.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Focused shock wave
Description: We delivered 2000 shots per session using a low/medium energy level (range between 0.01 and 0.175 milliJoule/mm2) depending on the patient's tolerance during treatment with a frequency of 4 Hz.
Study: NCT03503344

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT05449912

Intervention type: OTHER
Intervention: Collection of environmental exposure data
Description: noise pollution air pollution proximity and accessibility to green spaces, blue spaces
Study: NCT02742233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saxagliptin
Description: Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.~Treatment Period: Participants will receive saxagliptin with regular treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.~Treatment Period: Participants will receive placebo with regular treatment
Study: NCT04536935

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Mental Health App - 1
Description: Free mobile mental health application that focuses on meditation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Mental Health App - 2
Description: Free mobile mental health application that assists with coping with COVID-19

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Mental Health App - 3
Description: Free mobile mental health application that focuses on positive psychology.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mobile Mental Health App - 4
Description: Free mobile application that addresses mental health issues through mood tracking
Study: NCT00867997

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chemoactive (remineralizing, neuroactive) dentifrice treatment
Description: Chemoactive (remineralizing, neuroactive) dentifrice treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clearfil S3 Bond; Clearfil Liner Bond 2 Protect Liner F
Description: Self-etch DBA followed by a hydrophobic resin layer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clearfil S3 Bond; Premise Flowable resin-based composite
Description: Restoration with a dentin bonding agent (DBA) and flowable resin-based composite
Study: NCT04049110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forxiga 10mg
Description: Dapagliflozin 10mg per 24 hours, oral, for 7 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forxiga 10mg
Description: Dapagliflozin 10mg per 24 hours, oral, for 7 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 1 tablet per 24 hours, oral, for 7 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 1 tablet per 24 hours, oral, for 7 consecutive days
Study: NCT01704794

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid + Paludrine + Jobelyn (500mg)
Description: Combination of routine drugs + Jobelyn

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid + Paludrine + Jobelyn (250mg)
Description: Standard routine drugs for treatment of SCD with 250mg Jobelyn
Study: NCT01098331

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Radical Prostatectomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Brachytherapy
Study: NCT04333537

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography (CT)
Description: Undergo SPECT/CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Description: Undergo SPECT/CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imaging Agent
Description: Receive imaging agent via injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neck Dissection
Description: Undergo standard elective neck dissection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Planar Imaging
Description: Undergo planar imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy
Description: Undergo SLN biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT/CT scan
Study: NCT03767348

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP1
Description: Genetically modified herpes simplex type 1 virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP1
Description: Genetically modified herpes simplex type 1 virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP1
Description: Genetically modified herpes simplex type 1 virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP1
Description: Genetically modified herpes simplex type 1 virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP1
Description: Genetically modified herpes simplex type 1 virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP1
Description: Genetically modified herpes simplex type 1 virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP1
Description: Genetically modified herpes simplex type 1 virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP1
Description: Genetically modified herpes simplex type 1 virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP1
Description: Genetically modified herpes simplex type 1 virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP1
Description: Genetically modified herpes simplex type 1 virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: anti-PD-1 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: anti-PD-1 monoclonal antibody
Study: NCT03083665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: * Pharmaceutical form: Film-coated tablets~* Route of administration: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: * Pharmaceutical form: Film-coated tablets~* Route of administration: Oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Pharmaceutical form: Film-coated tablets~* Route of administration: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: * Pharmaceutical form: Film-coated tablets~* Concentration: 25 mg tablets and 50 mg tablets~* Route of administration: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: * Pharmaceutical form: Film-coated tablets~* Concentration: 25 mg tablets and 50 mg tablets~* Route of administration: Oral use
Study: NCT03933683

Intervention type: DEVICE
Intervention: Pudendal nerve terminal motor latency assessment
Description: After a specialized coloproctology evaluation, each patient with pelviperineal dysfunction was addressed to dynamic transperineal ultrasound to determine anterior and posterior displacement of puborectalis muscle, and subsequently a blinded neurophysiologist performed pudendal nerve terminal motor latency assessment to identify pudendal neuropathy.

Intervention type: DEVICE
Intervention: Pudendal nerve terminal motor latency assessment
Description: After a specialized coloproctology evaluation, each patient with pelviperineal dysfunction was addressed to dynamic transperineal ultrasound to determine anterior and posterior displacement of puborectalis muscle, and subsequently a blinded neurophysiologist performed pudendal nerve terminal motor latency assessment to identify pudendal neuropathy.
Study: NCT03201575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic conditioning
Description: A brachial cuff is positioned around the arm of the patient. Four cycles of \[5 min brachial cuff inflation at 200 mmHg followed by 5 min of cuff deflation\] started as soon as possible after randomization. The intervention is repeated at 12 and 24 hours after inclusion.

Intervention type: DEVICE
Group type: OTHER
Intervention: Patients with no remote ischemic conditioning
Description: A brachial cuff is positioned around the arm of the patient and no inflation or deflation is made.
Study: NCT03215628

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: TCEUS
Description: Intravenous sulphur hexafluoride microbubbles

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TCEUS
Description: Intravenous sulphur hexafluoride microbubbles

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: TCEUS
Description: Intravenous sulphur hexafluoride microbubbles
Study: NCT03443856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab and Ipilimumab
Description: Nivolumab 1 mg/kg IV Q3W plus Ipilimumab 3 mg/kg IV Q3W for 4 cycles (3 months) followed by nivolumab 240 mg flat-dose IV Q2W for 9 months.Total treatment time 1 year

Intervention type: OTHER
Group type: OTHER
Intervention: chemotherapy
Description: Completion of the perioperative treatment according to the 2016 ESMO guidelines (change of regimen is not allowed).
Study: NCT01580709

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multiple brushings
Description: Seven consecutive brush samples for cytology.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multimodality tissue sampling
Description: Single brush for cytology + single brush for FISH + cholangioscopy with site-directed biopsies
Study: NCT01008761

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin given at 10 mg/kg/day for day 1, then 5 mg/kg for 4 days Each syringe will contain 12.5 mls (250 mgs) sufficient drug to adequately dose children who with up to 25 kgs (95%tile for weight for 60 month old child)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Suspension Placebo
Description: Placebo suspension will be administered on day 1 at 10mg/kg and then for the next 4 days at 5 mg/kg
Study: NCT01506635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: artificial tear twice a day
Study: NCT02346227

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AV2
Description: The virucide AV2 consists of a spray. It is a mixture of natural essential oil components (Carvone, Eugenol, Geraniol, Nerolidol) in equal volumes diluted 50% in olive oil (Olea europaea).~It is administered as a topical spray to the cervix while the subject is in the lithotomic position and fitted with a speculum. The manual spray applicator is positioned inside the anterior of the vagina and two pumps are applied. Each pump delivers 100 microliters of the solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consists of 10% lemon (citrus limon) and 10% lime (citrus aurantifolia) in 80% olive oil.~It is administered as a one time (2 puffs) topical spray of 100 microliters on the cervix.
Study: NCT04047615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: An exercise intervention programme will be delivered in each school for an 8 week period. Exercise classes will take place 3 times a week and will be of 60 minutes duration.
Study: NCT03330678

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic (VSL#3)
Description: Each subject provided morning stool and venous blood ubes) specimens at three time-points, i.e. at baseline (before probiotic administration), after probiotic administration (VSL#3®, one capsule twice a day) for 4 weeks, and at 4 weeks after stopping the probiotic intake. Each capsule contained approximately 112.5 billion live freeze-dried bacteria (a mixture of eight species -- Streptococcus thermophilus, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, and Lactobacillus delbrueckii), which had been stored at 2-4ºC till ingestion.
Study: NCT03030352

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: How-to Parenting Program
Description: The How-to Parenting Program addresses all three key dimensions of optimal parenting; autonomy support, affiliation and structure. With weekly workshops, the How-to-Parenting Program optimizes learning by (1) linking group content with parents' needs, (2) facilitating awareness with perspective taking activities, (3) offering concrete parenting skills, (4) modeling the skills and providing practice in a predictable and non-judgmental environment, (5) emphasizing the importance of implementing these skills at home for long term behavioral change, and (6) offering tools (i.e., exercise booklet, skill summary) that facilitate information retention.
Study: NCT04372550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Resistance and aerobic exercise in addition to standard of care rehabilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care rehabilitation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care rehabilitation
Study: NCT01769664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel
Description: Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duac® Topical Gel
Description: Duac® (Clindamycin 1%/Benzoyl Peroxide 5%) Topical Gel (Stiefel) applied once a day in the evening for 77 days (11 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Topical Gel
Description: Placebo (Vehicle) Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)